Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Other Working Capital Changes (2016 - 2025)

Adma Biologics (ADMA) has disclosed Other Working Capital Changes for 13 consecutive years, with $547000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes rose 136.08% year-over-year to $547000.0, compared with a TTM value of $1.5 million through Dec 2025, down 43.41%, and an annual FY2025 reading of $1.5 million, down 43.41% over the prior year.
  • Other Working Capital Changes was $547000.0 for Q4 2025 at Adma Biologics, up from -$1.1 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $4.0 million in Q3 2024 and bottomed at -$1.6 million in Q1 2024.
  • Average Other Working Capital Changes over 5 years is $325400.0, with a median of -$64095.0 recorded in 2021.
  • The sharpest move saw Other Working Capital Changes skyrocketed 56704.25% in 2021, then crashed 767.84% in 2024.
  • Year by year, Other Working Capital Changes stood at -$1.5 million in 2021, then surged by 81.76% to -$277238.0 in 2022, then surged by 181.88% to $227000.0 in 2023, then plummeted by 767.84% to -$1.5 million in 2024, then soared by 136.08% to $547000.0 in 2025.
  • Business Quant data shows Other Working Capital Changes for ADMA at $547000.0 in Q4 2025, -$1.1 million in Q3 2025, and -$501000.0 in Q2 2025.